AllPennyStocks.com CAPR Stock Climbs On FDA’s Three-Month Deramiocel Extension — HC Wainwright Sticks To Neutral, Flags High Rejection Risk
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

CAPR Stock Climbs On FDA’s Three-Month Deramiocel Extension — HC Wainwright Sticks To Neutral, Flags High Rejection Risk

Capricor said on Monday that the FDA pushed back the deadline to decide on the company’s deramiocel application from August 22 to November 22.

Other Penny Stock Movers

Financial Tech Junior Surges 18% Following Reaffirmation of US$15.8M Digital Treasury
Quebec Gold Explorer Jumps 16% on C$57M Strategic Backing
$4.5 Million Could Unlock a Major Cannabis Market
Most Popular
{{ index + 1 }}


Back to Top